New oral cancer drug enters human testing
NCT ID NCT05025358
Summary
This first-in-human study tested a new oral medication called LP-118 in patients with advanced cancers that had stopped responding to other treatments. The main goals were to find a safe dose, see how the body processes the drug, and check for early signs that it might help control tumors. The trial included 68 adults with advanced solid tumors or lymphomas.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310006, China
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510080, China
-
The First Affiliated Hospital of Jinan University
Guangzhou, Guangdong, 510632, China
-
Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
Conditions
Explore the condition pages connected to this study.